BMX activates Wnt/β-catenin signaling pathway to promote cell proliferation and migration in breast cancer

  • Kai Li
  • Wen-ting Pan
  • Yan-bin Ma
  • Xiao-long Xu
  • Yang Gao
  • Yan-qi He
  • Lei Wei
  • Jing-wei ZhangEmail author
Original Article



Breast cancer has become a dangerous killer for the female, which seriously threatened women's life, leading to huge pressures to society. The present study assessed the mechanism underlying the involvement of bone marrow tyrosine kinase on chromosome X (BMX) in breast cancer development.


The expression of BMX was examined by qPCR and immunohistochemistry. The effect of BMX on cell proliferation and migration was detected by Clone formation assay and Transwell assay. In vitro study, the correlation of BMX with Wnt/β-catenin pathway was explored by western blot and TOP/FOP flash assay.


In the present study, we found that BMX was up-regulated in breast cancer, which was associated with the tumor differentiation and TNM stage. Oncogenic BMX enhanced the ability of breast cancer cell proliferation and migration. Furthermore, BMX could up-regulate the protein expression levels of p-β-catenin (Y142), p-β-catenin(Y654) and inhibit the expression level of p-β-catenin (S33/37), thus activating Wnt/β-catenin pathway in MCF-7 and MDA-MB-231 cells. In addition, we revealed that BMX promoted GSK3β phosphorylation, which suppressed the degradation of β-catenin.


In this study, we identified that BMX-activated Wnt/β-catenin signaling pathway, playing an oncogenic role in breast cancer, suggesting that BMX could become a potential treatment target of breast cancer.


BMX Breast cancer Wnt/β-catenin pathway Cell proliferation Migration 



This work was supported by the National Natural Science Foundation of China (81472765) and the Key Project of Science and Technology Department of Hubei Province (2015CFA070).

Compliance with ethical standards

Conflict of interest

All authors declare that they have no conflict of interest.


  1. 1.
    Botha JL, Bray F, Sankila R, Parkin DM. Breast cancer incidence and mortality trends in 16 European countries. Eur J Cancer. 2003;39:1718–29.CrossRefGoogle Scholar
  2. 2.
    Jung KW, Won YJ, Kong HJ, Oh CM, Seo HG, Lee JS. Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2010. Cancer Res Treat. 2013;45:1–14.CrossRefGoogle Scholar
  3. 3.
    Yoshimaru T, Komatsu M, Matsuo T, Chen YA, Murakami Y, Mizuguchi K, et al. Targeting BIG3-PHB2 interaction to overcome tamoxifen resistance in breast cancer cells. Nat Commun. 2013;4:2443.CrossRefGoogle Scholar
  4. 4.
    Flamini MI, Fu XD, Sanchez AM, Giretti MS, Garibaldi S, Goglia L, et al. Effects of raloxifene on breast cancer cell migration and invasion through the actin cytoskeleton. J Cell Mol Med. 2009;13:2396–407.CrossRefGoogle Scholar
  5. 5.
    Wang L, Liu L, Lou Z, Ding L, Guan H, Wang F, et al. Risk prediction for breast Cancer in Han Chinese women based on a cause-specific Hazard model. BMC Cancer. 2019;19:128.CrossRefGoogle Scholar
  6. 6.
    Weigelt B, Peterse JL, van't Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer. 2005;5:591–602.CrossRefGoogle Scholar
  7. 7.
    Talmadge JE. Clonal selection of metastasis within the life history of a tumor. Cancer Res. 2007;67:11471–5.CrossRefGoogle Scholar
  8. 8.
    Eldeeb MA, Fahlman RP. Phosphorylation impacts N-end rule degradation of the proteolytically activated form of BMX kinase. J Biol Chem. 2016;291:22757–68.CrossRefGoogle Scholar
  9. 9.
    Horwood NJ, Urbaniak AM, Danks L. Tec family kinases in inflammation and disease. Int Rev Immunol. 2012;31:87–103.CrossRefGoogle Scholar
  10. 10.
    Cenni B, Gutmann S, Gottar-Guillier M. BMX and its role in inflammation, cardiovascular disease, and cancer. Int Rev Immunol. 2012;31:166–73.CrossRefGoogle Scholar
  11. 11.
    van Oosterwijk JG, Buelow DR, Drenberg CD, Vasilyeva A, Li L, Shi L, et al. Hypoxia-induced upregulation of BMX kinase mediates therapeutic resistance in acute myeloid leukemia. J Clin Invest. 2018;128:369–80.CrossRefGoogle Scholar
  12. 12.
    Wang Q, Zeng F, Sun Y, Qiu Q, Zhang J, Huang W, et al. Etk Interaction with PFKFB4 modulates chemoresistance of small-cell lung cancer by regulating autophagy. Clin Cancer Res. 2018;24:950–62.CrossRefGoogle Scholar
  13. 13.
    Potter DS, Kelly P, Denneny O, Juvin V, Stephens LR, Dive C, et al. BMX acts downstream of PI3K to promote colorectal cancer cell survival and pathway inhibition sensitizes to the BH3 mimetic ABT-737. Neoplasia. 2014;16:147–57.CrossRefGoogle Scholar
  14. 14.
    Guo S, Sun F, Guo Z, Li W, Alfano A, Chen H, et al. Tyrosine kinase ETK/BMX is up-regulated in bladder cancer and predicts poor prognosis in patients with cystectomy. PLoS ONE. 2011;6:e17778.CrossRefGoogle Scholar
  15. 15.
    Chen KY, Huang LM, Kung HJ, Ann DK, Shih HM. The role of tyrosine kinase Etk/Bmx in EGF-induced apoptosis of MDA-MB-468 breast cancer cells. Oncogene. 2004;23:1854–62.CrossRefGoogle Scholar
  16. 16.
    Li Y, Cui N, Zheng PS, Yang WT. BMX/Etk promotes cell proliferation and tumorigenicity of cervical cancer cells through PI3K/AKT/mTOR and STAT3 pathways. Oncotarget. 2017;8:49238–52.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Shi Y, Guryanova OA, Zhou W, Liu C, Huang Z, Fang X, et al. Ibrutinib inactivates BMX-STAT3 in glioma stem cells to impair malignant growth and radioresistance. Sci Transl Med. 2018;10:eaah6816.CrossRefGoogle Scholar
  18. 18.
    Zhou W, Chen C, Shi Y, Wu Q, Gimple RC, Fang X, et al. Targeting glioma stem cell-derived pericytes disrupts the blood-tumor barrier and improves chemotherapeutic efficacy. Cell Stem Cell. 2017;21(591–603):e4.Google Scholar
  19. 19.
    Jaber M, Maoz M, Kancharla A, Agranovich D, Peretz T, Grisaru-Granovsky S, et al. Protease-activated-receptor-2 affects protease-activated-receptor-1-driven breast cancer. Cell Mol Life Sci. 2014;71:2517–33.CrossRefGoogle Scholar
  20. 20.
    Cohen I, Maoz M, Turm H, Grisaru-Granovsky S, Maly B, Uziely B, et al. Etk/Bmx regulates proteinase-activated-receptor1 (PAR1) in breast cancer invasion: signaling partners, hierarchy and physiological significance. PLoS ONE. 2010;5:e11135.CrossRefGoogle Scholar
  21. 21.
    Oladimeji P, Skerl R, Rusch C, Diakonova M. Synergistic activation of ERalpha by estrogen and prolactin in breast cancer cells requires tyrosyl phosphorylation of PAK1. Cancer Res. 2016;76:2600–11.CrossRefGoogle Scholar
  22. 22.
    Li K, Xu X, He Y, Tian Y, Pan W, Xu L, et al. P21-activated kinase 7 (PAK7) interacts with and activates Wnt/beta-catenin signaling pathway in breast cancer. J Cancer. 2018;9:1821–35.CrossRefGoogle Scholar
  23. 23.
    Varghese F, Bukhari AB, Malhotra R, De A. IHC Profiler: an open source plugin for the quantitative evaluation and automated scoring of immunohistochemistry images of human tissue samples. PLoS ONE. 2014;9:e96801.CrossRefGoogle Scholar
  24. 24.
    Yang Y, Shi J, Gu Z, Salama ME, Das S, Wendlandt E, et al. Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma. Cancer Res. 2015;75:594–604.CrossRefGoogle Scholar
  25. 25.
    Hamada-Kawaguchi N, Nore BF, Kuwada Y, Smith CI, Yamamoto D. Btk29A promotes Wnt4 signaling in the niche to terminate germ cell proliferation in Drosophila. Science. 2014;343:294–7.CrossRefGoogle Scholar
  26. 26.
    Zhou P, Li Y, Li B, Zhang M, Liu Y, Yao Y, et al. NMIIA promotes tumor growth and metastasis by activating the Wnt/beta-catenin signaling pathway and EMT in pancreatic cancer. Oncogene. 2019;38:5500–15.CrossRefGoogle Scholar
  27. 27.
    Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006;127:469–80.CrossRefGoogle Scholar
  28. 28.
    Bienz M, Clevers H. Armadillo/beta-catenin signals in the nucleus–proof beyond a reasonable doubt? Nat Cell Biol. 2003;5:179–82.CrossRefGoogle Scholar
  29. 29.
    Brembeck FH, Rosario M, Birchmeier W. Balancing cell adhesion and Wnt signaling, the key role of beta-catenin. Curr Opin Genet Dev. 2006;16:51–9.CrossRefGoogle Scholar
  30. 30.
    Miravet S, Piedra J, Castano J, Raurell I, Franci C, Dunach M, et al. Tyrosine phosphorylation of plakoglobin causes contrary effects on its association with desmosomes and adherens junction components and modulates beta-catenin-mediated transcription. Mol Cell Biol. 2003;23:7391–402.CrossRefGoogle Scholar
  31. 31.
    Rao TP, Kuhl M. An updated overview on Wnt signaling pathways: a prelude for more. Circ Res. 2010;106:1798–806.CrossRefGoogle Scholar

Copyright information

© The Japanese Breast Cancer Society 2019

Authors and Affiliations

  • Kai Li
    • 2
  • Wen-ting Pan
    • 2
  • Yan-bin Ma
    • 2
  • Xiao-long Xu
    • 2
  • Yang Gao
    • 2
  • Yan-qi He
    • 2
  • Lei Wei
    • 2
  • Jing-wei Zhang
    • 1
    Email author
  1. 1.Department of Breast and Thyroid Surgery, Zhongnan Hospital, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study CenterWuhan UniversityWuhanChina
  2. 2.Department of Pathology and Pathophysiology, Hubei Provincial Key Laboratory of Developmentally Originated Disease, School of Basic Medical SciencesWuhan UniversityWuhanChina

Personalised recommendations